This is the current release of the guideline.

Recommendation 1: Lipid-lowering therapy should be used for secondary prevention of cardiovascular mortality and morbidity for all patients (both men and women) with known coronary artery disease and type 2 diabetes.

Recommendation 2: Statins should be used for primary prevention against macrovascular complications in patients (both men and women) with type 2 diabetes and other cardiovascular risk factors.

Recommendation 3: Once lipid-lowering therapy is initiated, patients with type 2 diabetes mellitus should be taking at least moderate doses of a statin.

Recommendation 4: For those patients with type 2 diabetes who are taking statins, routine monitoring of liver function tests or muscle enzymes is not recommended except in specific circumstances.

None provided

The recommendations are supported by data from randomized controlled trials that included patients with diabetes. See related background article: Vijan S, Hayward RA; American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004 Apr 20;140(8):650-8.

Not applicable: The guideline was not adapted from another source.

2004 Apr 20

American College of Physicians - Medical Specialty Society

American College of Physicians

Clinical Efficacy Assessment Subcommittee (CEAS)

Authors: Vincenza Snow, MD; Mark D. Aronson, MD; E. Rodney Hornbake, MD; Christel Mottur-Pilson, PhD; Kevin B. Weiss, MD

Clinical Efficacy Assessment Subcommittee Members: Kevin Weiss, MD (Chair); Mark Aronson, MD; Patricia Barry, MD; Virginia Collier, MD; J. Thomas Cross Jr., MD; Nick Fitterman, MD; E. Rodney Hornbake, MD; Douglas K. Owens, MD; Katherine D. Sherif, MD

Financial support for this guideline comes exclusively from the American College of Physicians operating budget.

This is the current release of the guideline.

This NGC summary was completed by ECRI on July 1, 2004. The information was verified by the guideline developer on July 15, 2004.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.